Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Recommendation of “Moderate Buy” by Analysts
Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among […]
More Stories
Tariffs Temporarily Reinstated by Appeals Court, Reversing Lower Court Order
By Jack Phillips A federal appeals court on Thursday temporarily paused a lower-court ruling that struck down President Donald Trump’s...
How To Turn On Voice Chat In Roblox? (2025 Guide)
Voice Chat is among the best ways of coordinating with your team players and building strategies. This feature was among...
‘Ransom Canyon’ Season 2: Is the Wait Finally Over… or Just Beginning?
Ransom Canyon is an intense contemporary Western drama that dives into the depths of Texas Hill Country and the broad...
Apple to Skip iOS 19, Launch iOS 26 with Major Redesign at WWDC 2025
Apple will introduce a new operating system naming convention – iOS 26 at the Worldwide Developers Conference (WWDC) 2025 on...
Nuveen Asset Management LLC Trims Holdings in National Fuel Gas (NYSE:NFG)
Nuveen Asset Management LLC lessened its holdings in shares of National Fuel Gas (NYSE:NFG – Free Report) by 10.4% during...
79,507 Shares in Informatica Inc. (NYSE:INFA) Bought by Squarepoint Ops LLC
Squarepoint Ops LLC bought a new position in shares of Informatica Inc. (NYSE:INFA – Free Report) during the fourth quarter,...